Humira approved for use in moderate Crohn's disease

The licensed indications for Humira (adalimumab) have been extended to include the treatment of adults with moderately active Crohn's disease, in addition to use in severe disease.

NICE guidance recommending adalimumab for use in severely active Crohn’s disease has been in place since 2010 | SCIENCE PHOTO LIBRARY
NICE guidance recommending adalimumab for use in severely active Crohn’s disease has been in place since 2010 | SCIENCE PHOTO LIBRARY

The TNF-alpha inhibitor should be used only when the response to conventional therapy, including a corticosteroid and/or an immunosuppressant, is inadequate or when such therapies are not tolerated or are contraindicated. 

View Humira drug record

Further information: AbbVie


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Ranitidine in short supply after contamination fears prompt precautionary recall

Ranitidine in short supply after contamination fears prompt precautionary recall

GPs have reported shortages of ranitidine following...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Alzhok and ranitidine oral soln.
Use our...

Excessive steroid dosing highlighted in inflammatory bowel disease

Excessive steroid dosing highlighted in inflammatory bowel disease

Some patients with Crohn's disease or ulcerative colitis...